Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $41 Price Target

Needham analyst Ami Fadia has reiterated a Buy rating on ACADIA Pharmaceuticals (NASDAQ: ACAD) and maintained a price target of $41. This endorsement reflects confidence in the company's performance and market position.